Minkyu Kim

Minkyu Kim

Auto-generated profile, based on publicly available information

Minkyu Kim

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DGDavid E. Gordon
David E. Gordon
GJGwendolyn M. Jang
Gwendolyn M. Jang
MBMehdi Bouhaddou
Mehdi Bouhaddou
JXJiewei Xu
Jiewei Xu
KOKirsten Obernier
Kirsten Obernier
NKNevan J. Krogan
Nevan J. Krogan

1 August 2020 in Cell
Verified
Journal Article
Closed access
MBMehdi Bouhaddou
Mehdi Bouhaddou
DMDanish Memon
Danish Memon
BMBjoern Meyer
Bjoern Meyer
KWKris White
Kris White
VRVeronica V. Rezelj
Veronica V. Rezelj
NKNevan J. Krogan
Nevan J. Krogan

22 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DGDavid E. Gordon
David E. Gordon
GJGwendolyn M. Jang
Gwendolyn M. Jang
MBMehdi Bouhaddou
Mehdi Bouhaddou
JXJiewei Xu
Jiewei Xu
KOKirsten Obernier
Kirsten Obernier
MBMelanie Brewer
Melanie Brewer
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption 1,2 . There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 67 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.

1 October 2021 in Science
Verified
Journal Article
Closed access
MKMinkyu Kim
Minkyu Kim
JPJisoo Park
Jisoo Park
MBMehdi Bouhaddou
Mehdi Bouhaddou
KKKyumin Kim
Kyumin Kim
ARAjda Rojc
Ajda Rojc
NKNevan J. Krogan
Nevan J. Krogan
Mapping protein interactions driving cancer: Cancer is a genetic disease, and much cancer research is focused on identifying carcinogenic mutations and determining how they relate to disease progression. Three papers demonstrate how mutations are processed through networks of protein interactions to promote cancer (see the Perspective by Cheng and Jackson). Swaney et al . focus on head and neck cancer and identify cancer-enriched interactions, demonstrating how point mutant–dependent interactions of PIK3CA, a kinase frequently mutated in human cancers, are predictive of drug response. Kim et al . focus on breast cancer and identify two proteins functionally connected to the tumor-suppressor gene BRCA1 and two proteins that regulate PIK3CA. Zheng et al . developed a statistical model that identifies protein networks that are under mutation pressure across different cancer types, including a complex bringing together PIK3CA with actomyosin proteins. These papers provide a resource that will be helpful in interpreting cancer genomic data. —VV

1 October 2021 in Science
Verified
Journal Article
Closed access
FZFan Zheng
Fan Zheng
MKMarcus R. Kelly
Marcus R. Kelly
DRDana J. Ramms
Dana J. Ramms
MHMarissa L. Heintschel
Marissa L. Heintschel
KTKai Tao
Kai Tao
TITrey Ideker
Trey Ideker
Mapping protein interactions driving cancer: Cancer is a genetic disease, and much cancer research is focused on identifying carcinogenic mutations and determining how they relate to disease progression. Three papers demonstrate how mutations are processed through networks of protein interactions to promote cancer (see the Perspective by Cheng and Jackson). Swaney et al . focus on head and neck cancer and identify cancer-enriched interactions, demonstrating how point mutant–dependent interactions of PIK3CA, a kinase frequently mutated in human cancers, are predictive of drug response. Kim et al . focus on breast cancer and identify two proteins functionally connected to the tumor-suppressor gene BRCA1 and two proteins that regulate PIK3CA. Zheng et al . developed a statistical model that identifies protein networks that are under mutation pressure across different cancer types, including a complex bringing together PIK3CA with actomyosin proteins. These papers provide a resource that will be helpful in interpreting cancer genomic data. —VV

1 October 2021 in Science
Verified
Journal Article
Closed access
DSDanielle L. Swaney
Danielle L. Swaney
DRDana J. Ramms
Dana J. Ramms
ZWZhiyong Wang
Zhiyong Wang
JPJisoo Park
Jisoo Park
YGYusuke Goto
Yusuke Goto
NKNevan J. Krogan
Nevan J. Krogan
Mapping protein interactions driving cancer: Cancer is a genetic disease, and much cancer research is focused on identifying carcinogenic mutations and determining how they relate to disease progression. Three papers demonstrate how mutations are processed through networks of protein interactions to promote cancer (see the Perspective by Cheng and Jackson). Swaney et al . focus on head and neck cancer and identify cancer-enriched interactions, demonstrating how point mutant–dependent interactions of PIK3CA, a kinase frequently mutated in human cancers, are predictive of drug response. Kim et al . focus on breast cancer and identify two proteins functionally connected to the tumor-suppressor gene BRCA1 and two proteins that regulate PIK3CA. Zheng et al . developed a statistical model that identifies protein networks that are under mutation pressure across different cancer types, including a complex bringing together PIK3CA with actomyosin proteins. These papers provide a resource that will be helpful in interpreting cancer genomic data. —VV